Reaction
Eosinophilic Bronchitis reporting signals
As of the last recalculation, Eosinophilic Bronchitis appears in 200 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is RABEPRAZOLE (PRR 665.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Rabeprazole | 83 | 665.6 | 668.1 |
| Risedronate Sodium | 80 | 445.7 | 446.9 |
| Ciclesonide | 33 | 301.8 | 302.5 |
| Rabeprazole Sodium | 52 | 267.8 | 268.3 |
| Budesonide | 74 | 206.9 | 207.2 |
| Mepolizumab | 56 | 162.5 | 162.7 |
| Clopidogrel Bisulfate | 83 | 143.7 | 143.8 |
| Mercaptopurine | 17 | 111.4 | 111.5 |
| Fluticasone Furoate | 12 | 109.6 | 109.7 |
| Fluticasone Furoate And Vilanterol Trifenatate | 27 | 90.2 | 90.2 |